High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
about
Low-dose rate brachytherapy for men with localized prostate cancerHigh dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancerUniversity Cooperation Platform (UCP) between Christian-Albrechts-University Kiel (Germany) and Chiang Mai University (Thailand): implementation of image-guided gynecological brachytherapyIs robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer - between options.High-dose-rate brachytherapy boost for prostate cancer: rationale and techniqueProstate brachytherapy: HDR or seed implant.Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancerPhysical and psychosocial side-effects of brachytherapy: a questionnaire survey.Estimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment.Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients.Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.Stereotactic body radiation therapy for nonpulmonary primary tumors.Brachytherapy for prostate cancer: a systematic review.Combination surgery for erectile dysfunction and male incontinence.Ultrashort courses of adjuvant breast radiotherapy: wave of the future or a fool's errand?What do we know about the α/β for prostate cancer?Do theoretical potential and advanced technology justify the use of high-dose rate brachytherapy as monotherapy for prostate cancer?Progress and controversies: Radiation therapy for prostate cancer.Dose-Escalated Robotic SBRT for Stage I-II Prostate Cancer.High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy : A systematic review.Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.Dosimetric comparison of inverse optimization with geometric optimization in combination with graphical optimization for HDR prostate implantsComparison of IPSA and HIPO inverse planning optimization algorithms for prostate HDR brachytherapy.Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes.Virtual HDR CyberKnife SBRT for Localized Prostatic Carcinoma: 5-Year Disease-Free Survival and Toxicity Observations.High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer.High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical controlMultisource Rotating Shield Brachytherapy Apparatus for Prostate Cancer.Prostate cancer high dose-rate brachytherapy: review of evidence and current perspectives.Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer.Current trends in urethral stricture management.
P2860
Q24235544-111E107B-DDAE-4894-A949-7DCD98E9BA13Q26824608-A13E81C2-905D-4E63-BC43-21CF732F8C9AQ28083557-37CDE914-231C-4D60-93C4-F4DD02E70CBFQ30881854-6546EB03-4C5D-496F-A9E3-7591FF6595A3Q34342191-030296CB-CAF8-4ECC-8EE8-046669B13AC7Q34355194-F1971578-250A-46FF-B186-1FE0A4EC3E03Q34415519-7E95539F-9252-4EB2-B343-3EA0656EF1ABQ34500918-3B8732B8-72BD-408A-9BF6-9A6C367ED821Q35111775-559288C6-8A21-4F7A-AD3E-66B481B065E1Q36328572-F523DC9C-DDD3-44EA-BFDD-4CA9DB5E78BFQ36364403-D2A71834-D4CB-41B2-B3A2-A98E63F0BDC9Q36604355-3D9CAF22-A124-4B11-AF70-F62C913EE962Q36898133-18F44F63-0AD7-43AD-8A7E-2EE51C7CDE39Q37116581-3FF9CB71-6738-410E-B892-D041BD37819CQ37338255-2DC4042D-0AE3-4C0D-9545-A02D87573D62Q37591954-C6721512-ED54-4012-9741-109549289DFEQ37940192-D873D116-6F11-4A96-A47E-21E1B672F7D1Q37947111-79813259-083F-44CA-888C-8CAE5FF0A238Q38023478-B982FC93-601E-4FF5-BC04-D8123CDCB8A0Q38152466-2FF97657-E16F-4291-A13D-F501407C4D1DQ38252429-A270DC77-1300-47DA-88F0-E35BD37863C2Q38437266-BDD21BCD-E29F-47D8-A2C1-36F058C2C6EFQ38721676-5EB9A6CE-B636-45D1-8C72-38E2691D7BF6Q39340402-3FD81FC2-BB66-47D3-84B6-54AFD4C15646Q41224791-8C77B98A-4899-4568-A7FE-C4D395B872A6Q41706903-357A2756-37AF-4422-99BC-63FBFB0CE749Q41775778-F973DAB1-016D-4EF0-8D33-47BE09FBD116Q41925779-B667EFEF-E9DB-43EE-80C5-CA59B4DDD555Q41952367-79021101-591B-4C04-9200-44C0A131B09CQ42012657-F3B73FDC-CF3C-4A5E-B474-39AB4B7942F2Q47751134-0EA3CE56-F344-4F66-AE87-559E28BF51C1Q48101934-D2191D7E-0BB9-46D9-9BE2-FF94BA07C8D4Q48837209-CE3E8529-7730-4722-BA5B-868B8E364CF0Q52689213-50DBBE13-B649-4FFD-A3EF-316D25AB4F6D
P2860
High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
High dose rate brachytherapy a ...... low dose rate palladium seeds.
@en
High dose rate brachytherapy a ...... low dose rate palladium seeds.
@nl
type
label
High dose rate brachytherapy a ...... low dose rate palladium seeds.
@en
High dose rate brachytherapy a ...... low dose rate palladium seeds.
@nl
prefLabel
High dose rate brachytherapy a ...... low dose rate palladium seeds.
@en
High dose rate brachytherapy a ...... low dose rate palladium seeds.
@nl
P2093
P1476
High dose rate brachytherapy a ...... low dose rate palladium seeds.
@en
P2093
Alvaro A Martinez
Gary S Gustafson
Kenneth Goldman
Mitchell Hollander
Peter Y Chen
Raywin Huang
P304
P356
10.1097/01.JU.0000113299.34404.22
P407
P577
2004-03-01T00:00:00Z